Glyconanoparticles with Activatable Near-Infrared Probes for Tumor-Cell Imaging and Targeted Drug Delivery
Multifunctional nanocarriers based on tumor targeting and intracellular monitoring have received much attention and been a subject of intensive study by researchers in recent years. In this study, we report multifunctional glyconanoparticles with activatable near-infrared probes for tumor imaging an...
Saved in:
Published in | International journal of nanomedicine Vol. 17; pp. 1567 - 1575 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
New Zealand
Dove Medical Press Limited
01.01.2022
Dove Dove Medical Press |
Subjects | |
Online Access | Get full text |
ISSN | 1178-2013 1176-9114 1178-2013 |
DOI | 10.2147/IJN.S337082 |
Cover
Loading…
Abstract | Multifunctional nanocarriers based on tumor targeting and intracellular monitoring have received much attention and been a subject of intensive study by researchers in recent years. In this study, we report multifunctional glyconanoparticles with activatable near-infrared probes for tumor imaging and targeted drug delivery.
Disulfide-functionalized dicyanomethylene-4
-pyran (DCM-SS-NH
) and amino-functionalized lactose were modified and loaded onto the surfaces of polydopamine nanoparticles (NPs) by Michael addition or Schiff-base reaction as GSH stimulation-responsive fluorescent probes and tumor-targeting moieties, respectively. Doxorubicin (DOX), a model anticancer drug, was loaded onto polydopamine through π-π interactions directly to prepare multifunctional PLDD (PDA@Lac/DCM/DOX) NPs.
Experimental results showed that PLDD NPs had been successfully prepared. DCM, the fluorescence of which was quenched in PLDD NPs, was able to restore red fluorescence in a solution with a GSH concentration of 5 mM. The amount of DOX released from PLDD NPs was 44% over 72 hours in a weak-acid environment (pH 5). The results of CLSM and flow cytometry indicated that the PLDD NPs had good HepG2-targeting ability due to the special recognition between lactose derivative of NPs and overexpressed asialoglycoprotein receptors on HepG2 cell membrane. More importantly, the disulfide bond of DCM-SS-NH
was broken by the high concentration of GSH inside cancer cells, activating the near-infrared fluorescence probe DCM for cancer-cell imaging. MTT assays indicated that PLDD NPs exhibited higher anticancer efficiency for HepG2 cells and had reduced side effects on normal cells compared with free DOX.
The fluorescence of modified DCM loaded onto PLDD NPs is able to be restored in the high-concentration GSH environment within cancer cells, while improving the effectiveness of chemotherapy with reduced side effects. It provides a good example of integration of tumor imaging and targeted drug delivery. |
---|---|
AbstractList | Background: Multifunctional nanocarriers based on tumor targeting and intracellular monitoring have received much attention and been a subject of intensive study by researchers in recent years. In this study, we report multifunctional glyconanoparticles with activatable near-infrared probes for tumor imaging and targeted drug delivery. Methods: Disulfide-functionalized dicyanomethylene-4H-pyran (DCM-SS-[NH.sub.2]) and amino-functionalized lactose were modified and loaded onto the surfaces of polydopamine nanoparticles (NPs) by Michael addition or Schiff-base reaction as GSH stimulationresponsive fluorescent probes and tumor-targeting moieties, respectively. Doxorubicin (DOX), a model anticancer drug, was loaded onto polydopamine through n-n interactions directly to prepare multifunctional PLDD (PDA@Lac/DCM/DOX) NPs. Results: Experimental results showed that PLDD NPs had been successfully prepared. DCM, the fluorescence of which was quenched in PLDD NPs, was able to restore red fluorescence in a solution with a GSH concentration of 5 mM. The amount of DOX released from PLDD NPs was 44% over 72 hours in a weak-acid environment (pH 5). The results of CLSM and flow cytometry indicated that the PLDD NPs had good HepG2-targeting ability due to the special recognition between lactose derivative of NPs and overexpressed asialoglycoprotein receptors on HepG2 cell membrane. More importantly, the disulfide bond of DCM-SS-[NH.sub.2] was broken by the high concentration of GSH inside cancer cells, activating the near-infrared fluorescence probe DCM for cancer-cell imaging. MTT assays indicated that PLDD NPs exhibited higher anticancer efficiency for HepG2 cells and had reduced side effects on normal cells compared with free DOX. Conclusion: The fluorescence of modified DCM loaded onto PLDD NPs is able to be restored in the high-concentration GSH environment within cancer cells, while improving the effectiveness of chemotherapy with reduced side effects. It provides a good example of integration of tumor imaging and targeted drug delivery. Keywords: near-infrared probes, targeted drug delivery, GSH-responsive, tumor-cell imaging, polydopamine Multifunctional nanocarriers based on tumor targeting and intracellular monitoring have received much attention and been a subject of intensive study by researchers in recent years. In this study, we report multifunctional glyconanoparticles with activatable near-infrared probes for tumor imaging and targeted drug delivery. Disulfide-functionalized dicyanomethylene-4 -pyran (DCM-SS-NH ) and amino-functionalized lactose were modified and loaded onto the surfaces of polydopamine nanoparticles (NPs) by Michael addition or Schiff-base reaction as GSH stimulation-responsive fluorescent probes and tumor-targeting moieties, respectively. Doxorubicin (DOX), a model anticancer drug, was loaded onto polydopamine through π-π interactions directly to prepare multifunctional PLDD (PDA@Lac/DCM/DOX) NPs. Experimental results showed that PLDD NPs had been successfully prepared. DCM, the fluorescence of which was quenched in PLDD NPs, was able to restore red fluorescence in a solution with a GSH concentration of 5 mM. The amount of DOX released from PLDD NPs was 44% over 72 hours in a weak-acid environment (pH 5). The results of CLSM and flow cytometry indicated that the PLDD NPs had good HepG2-targeting ability due to the special recognition between lactose derivative of NPs and overexpressed asialoglycoprotein receptors on HepG2 cell membrane. More importantly, the disulfide bond of DCM-SS-NH was broken by the high concentration of GSH inside cancer cells, activating the near-infrared fluorescence probe DCM for cancer-cell imaging. MTT assays indicated that PLDD NPs exhibited higher anticancer efficiency for HepG2 cells and had reduced side effects on normal cells compared with free DOX. The fluorescence of modified DCM loaded onto PLDD NPs is able to be restored in the high-concentration GSH environment within cancer cells, while improving the effectiveness of chemotherapy with reduced side effects. It provides a good example of integration of tumor imaging and targeted drug delivery. Multifunctional nanocarriers based on tumor targeting and intracellular monitoring have received much attention and been a subject of intensive study by researchers in recent years. In this study, we report multifunctional glyconanoparticles with activatable near-infrared probes for tumor imaging and targeted drug delivery.BackgroundMultifunctional nanocarriers based on tumor targeting and intracellular monitoring have received much attention and been a subject of intensive study by researchers in recent years. In this study, we report multifunctional glyconanoparticles with activatable near-infrared probes for tumor imaging and targeted drug delivery.Disulfide-functionalized dicyanomethylene-4H-pyran (DCM-SS-NH2) and amino-functionalized lactose were modified and loaded onto the surfaces of polydopamine nanoparticles (NPs) by Michael addition or Schiff-base reaction as GSH stimulation-responsive fluorescent probes and tumor-targeting moieties, respectively. Doxorubicin (DOX), a model anticancer drug, was loaded onto polydopamine through π-π interactions directly to prepare multifunctional PLDD (PDA@Lac/DCM/DOX) NPs.MethodsDisulfide-functionalized dicyanomethylene-4H-pyran (DCM-SS-NH2) and amino-functionalized lactose were modified and loaded onto the surfaces of polydopamine nanoparticles (NPs) by Michael addition or Schiff-base reaction as GSH stimulation-responsive fluorescent probes and tumor-targeting moieties, respectively. Doxorubicin (DOX), a model anticancer drug, was loaded onto polydopamine through π-π interactions directly to prepare multifunctional PLDD (PDA@Lac/DCM/DOX) NPs.Experimental results showed that PLDD NPs had been successfully prepared. DCM, the fluorescence of which was quenched in PLDD NPs, was able to restore red fluorescence in a solution with a GSH concentration of 5 mM. The amount of DOX released from PLDD NPs was 44% over 72 hours in a weak-acid environment (pH 5). The results of CLSM and flow cytometry indicated that the PLDD NPs had good HepG2-targeting ability due to the special recognition between lactose derivative of NPs and overexpressed asialoglycoprotein receptors on HepG2 cell membrane. More importantly, the disulfide bond of DCM-SS-NH2 was broken by the high concentration of GSH inside cancer cells, activating the near-infrared fluorescence probe DCM for cancer-cell imaging. MTT assays indicated that PLDD NPs exhibited higher anticancer efficiency for HepG2 cells and had reduced side effects on normal cells compared with free DOX.ResultsExperimental results showed that PLDD NPs had been successfully prepared. DCM, the fluorescence of which was quenched in PLDD NPs, was able to restore red fluorescence in a solution with a GSH concentration of 5 mM. The amount of DOX released from PLDD NPs was 44% over 72 hours in a weak-acid environment (pH 5). The results of CLSM and flow cytometry indicated that the PLDD NPs had good HepG2-targeting ability due to the special recognition between lactose derivative of NPs and overexpressed asialoglycoprotein receptors on HepG2 cell membrane. More importantly, the disulfide bond of DCM-SS-NH2 was broken by the high concentration of GSH inside cancer cells, activating the near-infrared fluorescence probe DCM for cancer-cell imaging. MTT assays indicated that PLDD NPs exhibited higher anticancer efficiency for HepG2 cells and had reduced side effects on normal cells compared with free DOX.The fluorescence of modified DCM loaded onto PLDD NPs is able to be restored in the high-concentration GSH environment within cancer cells, while improving the effectiveness of chemotherapy with reduced side effects. It provides a good example of integration of tumor imaging and targeted drug delivery.ConclusionThe fluorescence of modified DCM loaded onto PLDD NPs is able to be restored in the high-concentration GSH environment within cancer cells, while improving the effectiveness of chemotherapy with reduced side effects. It provides a good example of integration of tumor imaging and targeted drug delivery. Guanyu Chi,* Yinghua Lv,* Shuang Chao,* Chenxi Hou, Yuxin Pei, Zhichao Pei Shaanxi Key Laboratory of Natural Products and Chemical Biology, College of Chemistry and Pharmacy, Northwest A&F University, Yangling, Shaanxi, 712100, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhichao Pei, Shaanxi Key Laboratory of Natural Products and Chemical Biology, College of Chemistry and Pharmacy, Northwest A&F University, Yangling, Shaanxi 712100, People’s Republic of China, Tel/Fax +86 29 8709-2769, Email peizc@nwafu.edu.cnBackground: Multifunctional nanocarriers based on tumor targeting and intracellular monitoring have received much attention and been a subject of intensive study by researchers in recent years. In this study, we report multifunctional glyconanoparticles with activatable near-infrared probes for tumor imaging and targeted drug delivery.Methods: Disulfide-functionalized dicyanomethylene-4H-pyran (DCM-SS-NH2) and amino-functionalized lactose were modified and loaded onto the surfaces of polydopamine nanoparticles (NPs) by Michael addition or Schiff-base reaction as GSH stimulation–responsive fluorescent probes and tumor-targeting moieties, respectively. Doxorubicin (DOX), a model anticancer drug, was loaded onto polydopamine through π–π interactions directly to prepare multifunctional PLDD (PDA@Lac/DCM/DOX) NPs.Results: Experimental results showed that PLDD NPs had been successfully prepared. DCM, the fluorescence of which was quenched in PLDD NPs, was able to restore red fluorescence in a solution with a GSH concentration of 5 mM. The amount of DOX released from PLDD NPs was 44% over 72 hours in a weak-acid environment (pH 5). The results of CLSM and flow cytometry indicated that the PLDD NPs had good HepG2-targeting ability due to the special recognition between lactose derivative of NPs and overexpressed asialoglycoprotein receptors on HepG2 cell membrane. More importantly, the disulfide bond of DCM-SS-NH2 was broken by the high concentration of GSH inside cancer cells, activating the near-infrared fluorescence probe DCM for cancer-cell imaging. MTT assays indicated that PLDD NPs exhibited higher anticancer efficiency for HepG2 cells and had reduced side effects on normal cells compared with free DOX.Conclusion: The fluorescence of modified DCM loaded onto PLDD NPs is able to be restored in the high-concentration GSH environment within cancer cells, while improving the effectiveness of chemotherapy with reduced side effects. It provides a good example of integration of tumor imaging and targeted drug delivery.Keywords: near-infrared probes, targeted drug delivery, GSH-responsive, tumor-cell imaging, polydopamine |
Audience | Academic |
Author | Lv, Yinghua Pei, Yuxin Pei, Zhichao Hou, Chenxi Chi, Guanyu Chao, Shuang |
Author_xml | – sequence: 1 givenname: Guanyu surname: Chi fullname: Chi, Guanyu – sequence: 2 givenname: Yinghua surname: Lv fullname: Lv, Yinghua – sequence: 3 givenname: Shuang surname: Chao fullname: Chao, Shuang – sequence: 4 givenname: Chenxi surname: Hou fullname: Hou, Chenxi – sequence: 5 givenname: Yuxin surname: Pei fullname: Pei, Yuxin – sequence: 6 givenname: Zhichao surname: Pei fullname: Pei, Zhichao |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35401000$$D View this record in MEDLINE/PubMed |
BookMark | eNptkk2P0zAQhiO0iP2AE3cUiQsSSvFXHOeCVHVhCVotSJSzNXHsrKvELo5b1H-PS8tqi1Y-eDR-5vWM_V5mZ847nWWvMZoRzKoPzde72Q9KKyTIs-wC40oUBGF69ig-zy6naYVQWQlev8jOackQRghdZKubYae8A-fXEKJVg57y3zbe53MV7RYitIPO7zSEonEmQNBd_j34NlHGh3y5GX0oFnoY8maE3ro-B9flSwi9jgm9Dps-v9aD3eqwe5k9NzBM-tVxv8p-fv60XHwpbr_dNIv5baEYY7HAVVcprrhQpuPKiJoohBitNTGcKVGa1hjKCScV0WnmWgjAtATGQPMSM0yvsuag23lYyXWwI4Sd9GDl34QPvTyOKjlipWA8XZwiRevadKSjSHFDaN0iSFofD1rrTTvqTmkXAwwnoqcnzt7L3m9l6qusMUkC744Cwf_a6CnK0U4qPRg47TeTJJzVpCSClgl9e0B7SK1ZZ3xSVHtczitEWSVISRM1e4JKq9OjTT-pjU35k4I3j0d46P2fBxLw_gCo4KcpaPOAYCT3DpPJYfLosETj_2hlI0Tr9_Pb4cmaP0S20WQ |
CitedBy_id | crossref_primary_10_2147_IJN_S471734 crossref_primary_10_3390_biom14080960 crossref_primary_10_1016_j_ijbiomac_2023_124294 crossref_primary_10_3390_vaccines10122049 crossref_primary_10_1039_D3QO00476G |
Cites_doi | 10.1002/adfm.201400419 10.1039/C5TB02525G 10.1016/j.cclet.2019.05.004 10.1016/j.biomaterials.2009.12.019 10.1039/c2cc31581e 10.1039/C8CC08252A 10.7150/thno.7341 10.2147/IJN.S152002 10.1021/acsami.9b09059 10.1002/ange.202009442 10.1016/j.cclet.2019.10.030 10.1021/ac504763b 10.1039/D1CC02959B 10.1021/acs.bioconjchem.1c00205 10.1021/acs.chemmater.6b01857 10.2147/IJN.S276470 10.1002/anie.201310508 10.1021/acs.analchem.8b02704 10.1039/C8TB02310G 10.1021/acs.accounts.6b00239 10.1021/bm2006856 10.2174/1381612821666150901103418 10.1039/C6CC03641D 10.1039/C9SC06337D 10.1021/jp0031395 10.1038/s41467-020-18520-7 10.1016/j.addr.2020.06.012 10.1021/acsami.7b06192 10.1002/adfm.202009924 10.1002/anie.201407272 10.1002/anie.201407182 10.2147/IJN.S191256 10.1016/j.gresc.2021.01.003 10.1039/D0CC04315J 10.1021/cr400407a 10.1016/j.jcis.2012.07.030 |
ContentType | Journal Article |
Copyright | 2022 Chi et al. COPYRIGHT 2022 Dove Medical Press Limited 2022 Chi et al. 2022 Chi et al. |
Copyright_xml | – notice: 2022 Chi et al. – notice: COPYRIGHT 2022 Dove Medical Press Limited – notice: 2022 Chi et al. 2022 Chi et al. |
DBID | AAYXX CITATION NPM 7X8 5PM |
DOI | 10.2147/IJN.S337082 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Engineering |
DocumentTitleAlternate | Chi et al |
EISSN | 1178-2013 |
EndPage | 1575 |
ExternalDocumentID | oai_doaj_org_article_6045846c44604c399fd2d30c6f239b0a PMC8985912 A703478253 35401000 10_2147_IJN_S337082 |
Genre | Journal Article |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GroupedDBID | --- 0YH 29J 2WC 53G 5GY 5VS 7X7 8FI 8FJ 8G5 AAYXX ABUWG ACGFO ADBBV ADRAZ AEGXH AENEX AFKRA AIAGR ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ BVXVI CCPQU CITATION CS3 DIK DU5 DWQXO E3Z EBD EBS EJD EMOBN F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HMCUK HYE IAO IHR ITC KQ8 M2O M48 MM. O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM SJN SV3 TDBHL TR2 UKHRP VDV NPM PMFND 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c444t-17d7c6c68cfd6cf892c00439e2f64c85fbff3626272e708988a135a44ae651413 |
IEDL.DBID | M48 |
ISSN | 1178-2013 1176-9114 |
IngestDate | Wed Aug 27 01:25:34 EDT 2025 Thu Aug 21 18:43:15 EDT 2025 Fri Jul 11 02:54:32 EDT 2025 Tue Jun 17 21:07:30 EDT 2025 Tue Jun 10 20:11:51 EDT 2025 Thu Apr 03 07:00:47 EDT 2025 Thu Apr 24 22:57:23 EDT 2025 Tue Jul 01 03:52:21 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | targeted drug delivery near-infrared probes tumor-cell imaging polydopamine GSH-responsive |
Language | English |
License | http://creativecommons.org/licenses/by-nc/3.0 2022 Chi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c444t-17d7c6c68cfd6cf892c00439e2f64c85fbff3626272e708988a135a44ae651413 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/IJN.S337082 |
PMID | 35401000 |
PQID | 2649252835 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_6045846c44604c399fd2d30c6f239b0a pubmedcentral_primary_oai_pubmedcentral_nih_gov_8985912 proquest_miscellaneous_2649252835 gale_infotracmisc_A703478253 gale_infotracacademiconefile_A703478253 pubmed_primary_35401000 crossref_primary_10_2147_IJN_S337082 crossref_citationtrail_10_2147_IJN_S337082 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-01-01 |
PublicationDateYYYYMMDD | 2022-01-01 |
PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New Zealand |
PublicationPlace_xml | – name: New Zealand |
PublicationTitle | International journal of nanomedicine |
PublicationTitleAlternate | Int J Nanomedicine |
PublicationYear | 2022 |
Publisher | Dove Medical Press Limited Dove Dove Medical Press |
Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
References | Shen (ref1) 2000; 104 Owens (ref7) 2016; 49 Chang (ref28) 2014; 53 Sun (ref5) 2021; 2 Poplinger (ref3) 2021; 32 Feng (ref6) 2018; 54 Zhou (ref12) 2020; 11 Liu (ref13) 2015; 87 Chao (ref4) 2020; 56 Lu (ref29) 2019; 14 Ball (ref25) 2012; 386 Zhang (ref22) 2018; 13 Wang (ref16) 2001; 24 Chao (ref31) 2021; 57 Mu (ref14) 2014; 53 Xing (ref15) 2014; 4 Li (ref24) 2016; 4 Wu (ref20) 2020; 31 Hou (ref32) 2020; 15 Liu (ref30) 2010; 31 Ji (ref9) 2020; 167 Kwon (ref27) 2018; 6 Xie (ref35) 2020; 31 Cao (ref18) 2016; 28 Yang (ref33) 2011; 12 Yang (ref36) 2016; 52 Feng (ref21) 2020; 11 Liu (ref23) 2014; 114 Zhu (ref10) 2020; 132 Chen (ref26) 2015; 21 Ding (ref34) 2019; 11 Song (ref11) 2021; 31 Zhao (ref8) 2018; 90 Cui (ref2) 2017; 9 Shang (ref17) 2014; 53 Guo (ref19) 2012; 48 |
References_xml | – volume: 24 start-page: 5443 year: 2001 ident: ref16 publication-title: Adv Funct Mater doi: 10.1002/adfm.201400419 – volume: 4 start-page: 2591 year: 2016 ident: ref24 publication-title: J Mater Chem B doi: 10.1039/C5TB02525G – volume: 31 start-page: 189 year: 2020 ident: ref20 publication-title: Chin Chem Lett doi: 10.1016/j.cclet.2019.05.004 – volume: 31 start-page: 2646 year: 2010 ident: ref30 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2009.12.019 – volume: 48 start-page: 6073 year: 2012 ident: ref19 publication-title: Chem Commun doi: 10.1039/c2cc31581e – volume: 54 start-page: 13626 year: 2018 ident: ref6 publication-title: Chem Commun doi: 10.1039/C8CC08252A – volume: 4 start-page: 290 year: 2014 ident: ref15 publication-title: Theranostics doi: 10.7150/thno.7341 – volume: 13 start-page: 2161 year: 2018 ident: ref22 publication-title: Int J Nanomed doi: 10.2147/IJN.S152002 – volume: 11 start-page: 28665 year: 2019 ident: ref34 publication-title: ACS Appl Mater Inter doi: 10.1021/acsami.9b09059 – volume: 132 start-page: 20383 year: 2020 ident: ref10 publication-title: Angew Chem Int Ed doi: 10.1002/ange.202009442 – volume: 31 start-page: 1173 year: 2020 ident: ref35 publication-title: Chin Chem Lett doi: 10.1016/j.cclet.2019.10.030 – volume: 87 start-page: 2550 year: 2015 ident: ref13 publication-title: Anal Chem doi: 10.1021/ac504763b – volume: 57 start-page: 7625 year: 2021 ident: ref31 publication-title: Chem Commun doi: 10.1039/D1CC02959B – volume: 32 start-page: 1641 year: 2021 ident: ref3 publication-title: Bioconjugate Chem doi: 10.1021/acs.bioconjchem.1c00205 – volume: 28 start-page: 4501 year: 2016 ident: ref18 publication-title: Chem Mater doi: 10.1021/acs.chemmater.6b01857 – volume: 15 start-page: 10417 year: 2020 ident: ref32 publication-title: Int J Nanomed doi: 10.2147/IJN.S276470 – volume: 53 start-page: 2 year: 2014 ident: ref17 publication-title: Angew Chem Int Ed doi: 10.1002/anie.201310508 – volume: 90 start-page: 8732 year: 2018 ident: ref8 publication-title: Anal Chem doi: 10.1021/acs.analchem.8b02704 – volume: 6 start-page: 6895 year: 2018 ident: ref27 publication-title: J Mater Chem B doi: 10.1039/C8TB02310G – volume: 49 start-page: 1731 year: 2016 ident: ref7 publication-title: Accounts Chem Res doi: 10.1021/acs.accounts.6b00239 – volume: 12 start-page: 3047 year: 2011 ident: ref33 publication-title: Biomacromolecules doi: 10.1021/bm2006856 – volume: 21 start-page: 4262 year: 2015 ident: ref26 publication-title: Curr Pharm Design doi: 10.2174/1381612821666150901103418 – volume: 52 start-page: 9316 year: 2016 ident: ref36 publication-title: Chem Commun doi: 10.1039/C6CC03641D – volume: 11 start-page: 1649 year: 2020 ident: ref21 publication-title: Chem Sci doi: 10.1039/C9SC06337D – volume: 104 start-page: 4 year: 2000 ident: ref1 publication-title: J Phys Chem B doi: 10.1021/jp0031395 – volume: 11 start-page: 1 year: 2020 ident: ref12 publication-title: Nat Commun doi: 10.1038/s41467-020-18520-7 – volume: 167 start-page: 121 year: 2020 ident: ref9 publication-title: Adv Drug Deliver Rev doi: 10.1016/j.addr.2020.06.012 – volume: 9 start-page: 25114 year: 2017 ident: ref2 publication-title: ACS Appl Mater Inter doi: 10.1021/acsami.7b06192 – volume: 31 start-page: 2009924 year: 2021 ident: ref11 publication-title: Adv Funct Mater doi: 10.1002/adfm.202009924 – volume: 53 start-page: 13126 year: 2014 ident: ref28 publication-title: Angew Chem Int Ed doi: 10.1002/anie.201407272 – volume: 53 start-page: 14357 year: 2014 ident: ref14 publication-title: Angew Chem Int Ed doi: 10.1002/anie.201407182 – volume: 14 start-page: 3525 year: 2019 ident: ref29 publication-title: Int J Nanomed doi: 10.2147/IJN.S191256 – volume: 2 start-page: 32 year: 2021 ident: ref5 publication-title: Green Synth Catal doi: 10.1016/j.gresc.2021.01.003 – volume: 56 start-page: 8861 year: 2020 ident: ref4 publication-title: Chem Commun doi: 10.1039/D0CC04315J – volume: 114 start-page: 5057 year: 2014 ident: ref23 publication-title: Chem Rev doi: 10.1021/cr400407a – volume: 386 start-page: 366 year: 2012 ident: ref25 publication-title: J Colloid Interf Sci doi: 10.1016/j.jcis.2012.07.030 |
SSID | ssj0057869 |
Score | 2.35204 |
Snippet | Multifunctional nanocarriers based on tumor targeting and intracellular monitoring have received much attention and been a subject of intensive study by... Background: Multifunctional nanocarriers based on tumor targeting and intracellular monitoring have received much attention and been a subject of intensive... Guanyu Chi,* Yinghua Lv,* Shuang Chao,* Chenxi Hou, Yuxin Pei, Zhichao Pei Shaanxi Key Laboratory of Natural Products and Chemical Biology, College of... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 1567 |
SubjectTerms | Cancer Chemotherapy Drug delivery systems Drugs Fluorescence gsh-responsive Investigations Lactose near-infrared probes Original Research polydopamine targeted drug delivery tumor cell imaging Vehicles |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swEBejT9tD6b5ab93QoDAouLUlWZYes2RdU1goLIW-CUWW2g7XGWny0P9-d7ITYlbYS1-jI8h3p_uQ7n5HyJHOgxRO6NSKQkOCUvFUBzCGEnyTtTZkVbzQ_zmR51fi4rq43hr1hTVhLTxwy7hTGV_ypIO0JRMO3GmoWMUzJwPjepbF0Aj-d51MtTYY1DAOs8vzEvUg521nHs7kOR1fTE5-cV5mivV8UYTs_9cwb3mmftXklhs62yO7XfxIB-2-X5MXvnlDXm2hCr4lv3_Uj5Dl2gby4a7sjeJ1Kx24OMsMm6XoBDQ8HTdhgQXo9BKbgh4oBLB0urqfL9Khr2s6vo8jjKhtKjqNFeNAOlqsbujI11jP8fiOXJ19nw7P026kQgoMFMs0L6vSSSeVC5V0QWnm8C1Qe4YiU0WYhYAANaxkHjiklbI5L6wQ1ksIrXL-nuw088YfEKoguGGFr2ZaKOGYst5BcOe0FRLsBCsScrxmrnEd3jiOvagN5B0oCQOSMJ0kEnK0If7Twmw8TfYNpbQhQWzs-ANojOlYav6nMQn5ijI2eIJhQ852jQjwWYiFZQZgBAUETgVPyGGPEk6e6y1_WWuJwSUsV2v8fPVgIMrUDGFzgAv7rdZs9owXbfiokpCyp0-9j-qvNHe3Efgb5FHonH14Di58JC8ZdnLE26RDsrNcrPwniK-Ws8_xKP0Fji0e4Q priority: 102 providerName: Directory of Open Access Journals |
Title | Glyconanoparticles with Activatable Near-Infrared Probes for Tumor-Cell Imaging and Targeted Drug Delivery |
URI | https://www.ncbi.nlm.nih.gov/pubmed/35401000 https://www.proquest.com/docview/2649252835 https://pubmed.ncbi.nlm.nih.gov/PMC8985912 https://doaj.org/article/6045846c44604c399fd2d30c6f239b0a |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1ra9swUPTxZfsw9l66LmhQGAzcxbIsWR_GSF9LCg1lSyD7JBRZ6lZcZ3MSWP797hQnxFvZF2OsM0h3J91D9yDkSMVecMtVZHiqwEDJk0h5OAwFyCZjjO_kwaF_NRC9Eb8cp-Mdsm7GWSNwdq9ph_2kRlVx_PvX8hNs-I8Yxhxz-aF_OTj-miQSpNku2QeRJHGHXvHNdQJwZehtF8cS2SJOVol6f__cEE2hgv-_5_SWoGoGUW5JpYvH5FGtTtLuiv5PyI4rn5KHW0UGn5Hbz8USjF5TgnlcR8FR9L7Srg2tzTB3ig6A4aN-6SuMR6fXmCM0o6DP0uHiblpFp64oaP8udDSipszpMASQA-hZtbihZ67A8I7lczK6OB-e9qK6w0JkOefzKJa5tMKKzPpcWJ8pZvFqUDmGFMxSP_Ee69UwyRxgSGWZiZPUcG6cAE0rTl6QvXJauleEZqDrsNTlE8UzbllmnAVdzyrDBRwbLG2R92vkaluXH8cuGIUGMwQpoYESuqZEixxtgH-uqm7cD3aCVNqAYKns8GFa3egapVqEq2ABC4Y3C_qYz1medKzwLFGTjmmRd0hjjSwGE7KmzkuAZWFpLN2FM5GDHpUmLXLYgISNaBvDb9dconEIo9dKN13MNCidimEVHcDCyxXXbOaMfje8Y2kR2eCnxqKaI-WP76EOONAjVTE7-P-0XpMHDFM2gtvokOzNq4V7A4rUfNImu51vPXjKsWyT_ZPzwfWXdnBKtMP2-QPcBh1- |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Glyconanoparticles+with+Activatable+Near-Infrared+Probes+for+Tumor-Cell+Imaging+and+Targeted+Drug+Delivery&rft.jtitle=International+journal+of+nanomedicine&rft.au=Chi%2C+Guanyu&rft.au=Lv%2C+Yinghua&rft.au=Chao%2C+Shuang&rft.au=Hou%2C+Chenxi&rft.date=2022-01-01&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-2013&rft.volume=17&rft.spage=1567&rft_id=info:doi/10.2147%2FIJN.S337082&rft.externalDocID=A703478253 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-2013&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-2013&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-2013&client=summon |